HKU Scholars Hub: Browsing DSpace

Browsing by Author Cheng, AL

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 10 to 22 of 22 < previous

	Title	Author(s)	Issue Date	Views
	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC) Proceeding/Conference:Journal of Clinical Oncology	Cheng, AL Cornelio, GH Shen, L Price, TJ Yang, TS Chung, IJ Dai, G Lin, JK Sharma, A Yeh, KH Ma, B Zaatar, A Guan, ZZ Masood, N Srimuninnimit, V Yau, TCC Sarholz, B Lim, RSC	2013	160
	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study Journal:Clinical Colorectal Cancer	Cheng, AL Cornelio, G Shen, L Price, T Yang, TS Chung, IJ Dai, GH Lin, JK Sharma, A Yeh, KH Ma, B Zaatar, A Guan, Z Masood, N Srimuninnimit, V Yau, TCC Gibbs, P Wang, X Doval, DC Seung-Taek, O Shim, BY Gorospe, C Wang, HM Sirachainan, E Hill, A Suh, KW Beier, F Chatterjee, S Lim, R	2017	79
	Health-Related Quality-of-Life Impact of Pembrolizumab Versus Best Supportive Care in Previously Systemically Treated Patients With Advanced Hepatocellular Carcinoma: KEYNOTE-240 Journal:Cancer	Ryoo, BY Merle, P Kulkarni, AS Cheng, AL Bouattour, M Lim, HY Breder, V Edeline, J Chao, Y Ogasawara, S Yau, T Garrido, M Chan, SL Daniele, B Norquist, JM Chen, E Siegel, AB Zhu, AX Finn, RS Kudo, M	2021	28
	Liver cancer working group report Journal:Japanese Journal of Clinical Oncology	Kudo, M Han, KH Kokudo, N Cheng, AL Choi, BI Furuse, J Izumi, N Park, JW Poon, RT Sakamoto, M	2010	161
	Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012 Journal:Lancet Oncology	Ku, G Tan, IB Yau, TCC Boku, N Laohavinij, S Cheng, AL Kang, YK de Lima Lopes, G	2012	44
	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial Journal:Liver Cancer	Kudo, M Lim, HY Cheng, AL Chao, Y Yau, TCC Ogasawara, S Kurosaki, M Morimoto, N Ohkawa, K Yamashita, T Lee, KH Chen, E Siegel, AB Ryoo, BY	2020	38
	Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study Journal:Clinical Cancer Research	Finn, RS Kudo, M Cheng, AL Wyrwicz, L Ngan, RKC Blanc, JF Baron, AD Vogel, A Ikeda, M Piscaglia, F Han, KH Qin, S Minoshima, Y Kanekiyo, M Ren, M Dairiki, R Tamai, T Dutcus, CE Ikezawa, H Funahashi, Y Evans, TRJ	2021	14
	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma Journal:Hepatology	Cheng, AL Thongprasert, S Lim, HY Sukeepaisarnjaroen, W Yang, TS Wu, CC Chao, Y Chan, SL Kudo, M Ikeda, M Kang, YK Pan, H Numata, K Han, G Balsara, B Zhang, Y Rodriguez, AM Zhang, Y Wang, Y Poon, RTP	2016	74
	Recent advances in the prevention of hepatocellular carcinoma recurrence Journal:Seminars in Liver Disease	Lu, LC Cheng, AL Poon, RTP	2014	51
	Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study Journal:Journal of Clinical Oncology	Kelley, RK Sangro, B Harris, W Ikeda, M Okusaka, T Kang, YK Qin, S Tai, DWM Lim, HY Yau, T Yong, WP Cheng, AL Gasbarrini, A Damian, S Bruix, J Borad, M Bendell, J Kim, TY Standifer, N He, P Makowsky, M Negro, A Kudo, M Abou-Alfa, GK	2021	23
	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial Journal:ESMO Open	Kelley, RK Ryoo, BY Merle, P Park, JW Bolondi, L Chan, SL Lim, HY Baron, AD Parnis, F Knox, J Cattan, S Yau, T Lougheed, JC Milwee, S El-Khoueiry, AB Cheng, AL Meyer, T Abou-Alfa, GK	2020	29
	Serum alpha-fetoprotein levels and clinical outcome in the phase 3 CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma Journal:Clinical Cancer Research	Kelley, RK Meyer, T Rimassa, L Merle, P Park, JW Yau, T Chan, SL Blanc, JF Tam, VC Tran, A Dadduzio, V Markby, DW Kaldate, R Cheng, AL El-Khoueiry, AB Abou-Alfa, GK	2020	32
	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma Journal:Journal for ImmunoTherapy of Cancer	Greten, TF Abou-Alfa, GK Cheng, AL Duffy, AG El-Khoueiry, AB Finn, RS Galle, PR Goyal, L He, AR Kaseb, AO Kelley, RK Lencioni, R Lujambio, A Mabry Hrones, D Pinato, DJ Sangro, B Troisi, RI Wilson Woods, A Yau, T Zhu, AX Melero, I	2021	24

Showing results 10 to 22 of 22 < previous